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Background:Nowadays, as a result of more liberal selection criteria, dialysis-dependent patients have become substantially
older, more likely to be female and diabetic, and have more comorbidity. The 1-year primary patency rates of
arteriovenous fistulas (AVFs) are poor. To improve these results, several secondary interventions can be performed. The
aim of this study was to evaluate the results after secondary interventions in patients with an upper extremity AVF.
Methods: Between January 2000 and December 2008, all consecutive patients who underwent construction of an
autologous upper extremity AVF were included. Patient characteristics were collected retrospectively from digital patient
files and a prospectively recorded database on hemodialysis patients.
Results: Between January 2000 and December 2008, 736 hemodialysis access procedures were performed. A total of 347
autologous arteriovenous fistulas (AVFs) were created in 294 patients. The mean age was 62.1  14.7 years, and the
majority (66%) of the patients was male. Mean follow-up of all 347 fistulas was 21.9  21.6 months. During follow-up,
failure occurred in 209 (60%) of the AVFs. A total of 133 of these failures were followed by a secondary intervention, of
which 78 (59%) were endovascular interventions. Twenty-nine patients developed a third failure, and 25 of these patients
underwent another intervention, of which 22 were percutaneous transluminal angioplasty for stenosis. Fifteen patients
developed a fourth failure, and all of them underwent an intervention. One patient had 11 interventions. The 1- and
2-year primary patency rates were 46% and 36.8%, respectively. The 1- and 2-year primary assisted patency rates were
74.6% and 71.2%, respectively. The 1- and 2-year secondary patency rates were 79.2% and 77.8%, respectively.
Conclusion: The primary patency rate of AVFs is disappointing. However, due to mostly endovascular secondary
interventions, 2-year primary assisted and secondary patency rates of more than 70% can be obtained. (J Vasc Surg 2011;
54:1095-9.)
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aIn the past 10 years, the number of dialysis-dependent
patients has increased with an estimate of 3.2% each year.1
In the United States, more than 341,000 patients are
dialysis-dependent.2 Currently in The Netherlands, about
6275 people are dialysis-dependent, of these 18% receives
peritoneal dialysis.1
Creating an arteriovenous fistula (AVF) is a method to
achieve long-term hemodialysis access for patients with
end-stage renal disease (ESRD). Since the introduction of
intermittent hemodialysis by Scribner in 1960 and the
introduction of the Brescia-Cimino fistula in 1966, sur-
geons are trying to improve patency rates of vascular access
sites for intermittent hemodialysis.3,4 The National Kidney
Foundation Dialysis Outcome and Quality Initiative
(NKF-DOQI) and the European Best Practice Guidelines
on Vascular Access recommend the use of an upper extrem-
From the Department of Vascular Surgery,a Department of Radiology,b and
Department of Nephrology,c Maasstad Hospital.
Competition of interest: none.
Reprint requests: Andre A. De Smet, MD, PhD, Department of Surgery,
Maasstad Hospital, Maasstadweg 21, 3079 DZ, Rotterdam, The Nether-
lands (e-mail: smeta@maasstadziekenhuis.nl).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00a
Copyright © 2011 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2011.04.023ty AVF instead of a prosthetic hemodialysis graft, and this
hould be placed as distal as possible.5-9
Nowadays, as a result of more liberal selection criteria,
ialysis-dependent patients have become substantially
lder, more likely to be female and diabetic, and have
igher comorbidity. Since they have poorer-quality blood
essels, construction of an AVF in the majority of these
atients results in increased primary failure and decreased
rimary patency rates.10,11 At 1 year, the primary patency
ates of autologous fistulas reported in recent literature
aries from 36% to 62.5%.12-18 To improve this marginal
esult, several secondary interventions can be performed.
specially percutaneous transluminal angioplasty (PTA) is
erformed frequently, but also accessory vein ligation,
atching, thrombectomy, and urokinase treatment.19,20
The aim of this study was to evaluate the results of
econdary interventions in patients with an upper extremity
VF.
ATIENTS AND METHODS
Between January 2000 and December 2008, all con-
ecutive patients who underwent construction of an upper
xtremity autologous AVF were included. AVFs included
adiocephalic,4 brachiocephalic, Gracz21 fistulas (defined as
n autologous fistula constructed between the brachial
rtery and a branch of the medial antecubital vein, the
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October 20111096 Ayez et alperforating vein, below the elbow), and basilic vein trans-
positions.22 Patient characteristics were collected retro-
spectively from digital patient files and a prospectively
recorded database on hemodialysis patients (Diamant; Dia-
soft BV Leusden, The Netherlands). The database com-
prised data on age, gender, comorbidity, primary kidney
disease, fistula history, preoperative and postoperative du-
plex data, type of surgery, first use date, malfunction,
interventions, and complications.
Preoperative assessment. Preoperative work-up in-
cluded physical examination and duplex ultrasound (DUS).
Arterial patency was assessed by arterial pulse examination
and performance of the Allen test. Venous evaluation con-
sisted of examination of the veins of the upper arm, cubital
fossa, and lower arm with a tourniquet in place. Preferably,
the nondominant arm was evaluated with DUS. The diam-
eter and peak systolic velocity (PSV) of the radial, ulnar, and
brachial artery were measured. The vein diameter and
depth of the vein in the arm was assessed. Patients were
eligible for surgery if both the artery and vein contained no
stenosis, and the diameter was larger than 2 mm.
Surveillance. Four weeks after surgery, DUS was per-
formed. If an early stenosis was assessed, patients were
scheduled for PTA to improve maturation. A significant
stenosis was defined as a PSV ofminimal 400 cm/s onDUS
or a luminal diameter reduction of 50% on angiogra-
phy.23,24 When a declining flow was measured during
dialysis, patients were referred for DUS and, in case of a
stenosis, a PTA was performed. If a stenosis could not be
treated endovascularly, a patch plasty was performed.
Definitions. Patency rates were defined and calculated
as described by Sidawy.25 Primary patency was defined as
the interval from the time of access placement until any
intervention designed to maintain or re-establish patency
access. Primary assisted patency was defined as the interval
from the time of access placement until access thrombosis,
including interventions designed to maintain the function-
ality of a patent access. Secondary patency was defined as
the interval from the time of access placement until access
abandonment or thrombosis, including intervening manip-
ulations designed to re-establish functionality in throm-
bosed access. Fistula failure was defined as any event that
required an intervention to maintain or re-establish pa-
tency, including stenosis, thrombosis, pseudoaneurysm,
infection, hemorrhage, ischemia of the hand, and patient
dissatisfaction leading to another type of access.
Statistics. Measured values are reported as mean  1
standard deviation (SD) or median (range), as appropriate.
Comparison between categorical variables was determined
with the 2 test. Patency rates were calculated with the
Kaplan-Meier method. Patency rates were based on a per-
fistula analysis. Comparison between survival curves was
made by log-rank test. A statistical software package (SPSS
Version 15.0; SPSS Inc, Chicago, Ill) was used for statistical
analysis, where P  .05 was considered statistically signifi-
cant. uESULTS
Demographics. Between January 2000 and Decem-
er 2008, 736 hemodialysis access procedures were per-
ormed. A total of 347 autologous AVFs were created in
94 patients (Tables I and II). A total of 47 patients
nderwent placement of a second AVF, five patients under-
ent a third autologous access placement, and one patient
nderwent a fourth. Themean age ( SD)was 62.1 14.7
ears. The majority of the patients were male (66%).
Fistula failure and secondary interventions. Failure
ccurred in 209 (60%) AVFs. A total of 133 secondary
nterventions were performed of which 78 (59%) were
ndovascular interventions (Table III). Eighty of these
atients developed a second fistula failure, and 69 under-
ent a third intervention, of which 48 were PTA for
tenosis. Twenty-nine patients developed a third failure,
nd 25 of these patients underwent another intervention,
f which 22 were PTA for stenosis. Fifteen patients devel-
ped a fourth failure, and all of them underwent an inter-
ention. One patient had 11 interventions.
A total of 14 fistulas did not mature. Of these, nine
ere radiocephalic, two brachiocephalic, two basilica trans-
ositions, and one Gracz. In 10 patients, nonmaturation
as the result of stenosis and in three patients, accessory
eins. In one patient, the cause of nonmaturation was
able I. Patient characteristics
Patients (%)
ex
Male 195 (66)
Female 99 (34)
ean age (years)  SD 62.1  14.7
omorbidity
Hypertension 221 (75)
Cardiac disease 146 (50)
Hyperlipidemia 139 (47)
Diabetes mellitus 112 (38)
Pulmonary disease 51 (17)
Carotid disease 16 (5)
rimary renal disease
Hypertension nephropathy 84 (29)
Diabetic nephropathy 83 (28)
Glomerulonephritis 37 (13)
Polycystic renal disease 16 (5)
Othera 74 (25)
Other: atherosclerosis, cardial, laxatives abuses, drugs abuses, eci, M.
ahler, postrenal obstruction, relapsing urinary tract infection, SLE.
able II. Hemodialysis access procedures
Procedures (%)
Total 347 (100)
Radiocephalic AVF 179 (52)
Brachiocephalic AVF 73 (21)
Basilic vein transposition 62 (18)
Gracz 33 (10)
VF, Arteriovenous fistula.nknown.
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Volume 54, Number 4 Ayez et al 1097A total of 15 patients developed “steal.” Seven patients
could be treated conservatively because of mild complaints,
and eight had to be treated surgically by banding or another
surgical revision of the arterial flow (revision using distal
inflow or distal revascularization with interval ligation pro-
cedure). No arteriovenous fistula was ligated.
Patency rates. Mean follow-up of all 347 fistulas was
21.9  21.6 months. The 1- and 2-year primary patency
rates of all AVFs were 46% and 36.8%, respectively (Table
IV). No significant difference between the different types of
AVFs was observed (P  .673). The primary assisted pa-
tency rates were 74.6% at 1 year and 71.2% at 2 years. The
secondary patency rates were 79.2% at 1 year and 77.8% at
2 years. Again, no significant differences between the dif-
ferent types of AVFs were observed for primary assisted and
secondary patency rates (P  .547 and P  .561, respec-
Table III. The first failures and intervention of the AVF
Number (%)
First failure 209 (60)
Stenosis 122 (35)
Thrombosis 43 (12)
Steal 15 (4.3)
Bleeding 8 (2.3)
Pseudoaneurysm 5 (1.4)
Infection 2 (0.6
Inaccessible basilic vein 1 (0.3)
Unknown 9 (2.6)
First intervention 133
Radiocephalic AVF
PTA 41 (31)
Venous interposition graft 7 (5)
Patch repair 7 (5)
Thrombectomy 4 (3)
PTFE interposition graft 4 (3)
Ligation of accessory veins 3 (2)
Transposition of the AVF 2 (2)
Surgical hemostasis bleeding access site 1 (1)
Brachiocephalic AVF
PTA 14 (11)
Banding 3 (2)
Patch repair 3 (2)
PTFE interposition graft 2 (2)
Thrombectomy 1 (1)
Ligation of accessory veins 1 (1)
Transposition of the AVF 1 (1)
Basilic vein transposition
PTA 18 (14)
PTA  bare stent 1 (1)
Thrombectomy 4 (3)
Surgical hemostasis bleeding access site 3 (2)
PTFE interposition graft 1 (1)
Patch repair 1 (1)
Banding 1 (1)
Gracz
PTA 5 (4)
Surgical hemostasis bleeding access site 2 (2)
Thrombectomy 1 (1)
Transposition of the AVF 2 (2)
AVF, Arteriovenous fistula; PTA, percutaneous transluminal angioplasty;
PTFE, polytetrafluoroethylene.tively). pWhen patency rates for open revision vs endovascular
evision are compared in all 133 patients, the primary
ssisted patency was 50% at 1 year and 44% at 2 years for the
pen revisions, and 89% at 1 year and 84% at 2 years
P  .001) for the endovascular revisions. The secondary
atency was 73% at 1 year and 70% at 2 years for the open
evisions, and 92% at 1 year and 90% at 2 years (P  .001)
or the endovascular revisions.
The secondary patency rates for patent fistulas at time
f revision was 86% at 1 year and 85% at 2 years vs a
econdary patency of thrombosed fistulas at time of revision
f 70% at 1 year and 64% at 2 years (P  .100).
No significant difference was observed in primary, pri-
ary-assisted, and secondary patency rates between dia-
etic patients and patients with other causes of renal failure
P  .691, P  .068, and P  .215, respectively).
The secondary patency rates in patients who received
wo or more interventions were not different from patients
ho only underwent one intervention (P  .543).
ISCUSSION
Since the introduction of the KDOQI guidelines, there
as been a significant increase in the construction of autol-
gous AVFs for chronic hemodialysis access, when com-
ared to arteriovenous grafts.26 Although the autologous
VF is considered the golden standard, the reported 1-year
atency rates vary from 36% to 62.5%.12-18 In our series,
he primary patency was 46% at 1-year follow-up, but
ropped to 36.8% after 2 years. Following frequent, mostly
ndovascular, secondary interventions, we observed pri-
ary assisted and secondary patency rates of more than 70%
fter 2 years. The disappointing primary patency rates
ight be a result of the population’s substantial comorbid-
ty. Hypertension and cardiac comorbidity was observed in
t least half of the population. Hyperlipidemia and diabetes
ellitus was observed in 47% and 38%, respectively. As
uch as 54% of the AVFs failed in the first year following
onstruction and no 42% in the first 6 months.
In contrast to the primary patency rates, the primary
ssisted and secondary patency rates are promising. The
ost frequent cause of failure is a juxta-anastomotic steno-
is.27 In the present series, a significant stenosis developed
n about one-third of all AVFs. Of these stenoses, 70%
79/113) were treated endovascularly. High technical suc-
ess rates have been reported, but the patency rates are only
oderate.28 In a series of 536 percutaneous transvenous
ngioplasty procedures in the treatment of vascular access
tenosis, the technical success rate was 94%. However, the
atency rate had dropped to 38% after 1 year.19 In our
eries, 61% (48/79) of patients treated with PTA for their
rst failure underwent a second PTA during follow-up. In a
ecent nonrandomized study, surgical and endovascular
reatment of anastomotic and juxta-anastomotic stenoses
ere compared. Angioplasty and surgery showed similar
esults, but repeat procedures were more frequent with
ngioplasty.29 In a recent randomized study byHaskal et al,
tent placement resulted in significant less restenosis com-
ared with angioplasty in venous anastomotic stenoses in
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stent placement might also be beneficial in patients with
autologous AVF stenosis, but data are lacking. Although
PTA is a valuable and elegant treatment for AVF stenoses, it
is associated with a high rate of restenosis in comparison
with surgical treatment.
Formerly, thrombosis was managed by mechanical em-
bolectomy, but nowadays thrombosed fistulae can often be
treated percutaneously by thrombolysis (medicinal, me-
chanical, or both).7,31 Currently, urokinase, streptokinase,
and tissue plasminogen activator are all being used for
infusion thrombolysis.32 After dissolving the thrombosis,
any responsible stenosis may be treated immediately. In
addition, a combination of mechanical and thrombolytic
therapy is possible with a thrombolysis catheter with two
occluding balloons, drug infusion holes between the bal-
loons, and mechanical drug dispersion capabilities (Trellis;
Bacchus Vascular, Inc, Santa Clara, Calif). Several methods
for mechanical declotting have been described with high
technical and clinical success rates.31 In patients with a
reocclusion after minimal invasive thrombolysis, surgery is
the preferred treatment for fistula salvage. A study by Crikis
et al suggests that reocclusion within 1 month after radio-
logical intervention is best managed by surgery.33 Lipari et
al demonstrated that surgery remains a valid option to
salvage clotted AVFs.34 They recommend replacement of
the stenosed segment with a polytetrafluoroethylene graft
interposition rather than a proximal neo-anastomosis. They
also state that it is better to treat a stenosis pre-emptively
than postthrombosis, since AVF occlusion was associated
with an eightfold increased risk of access loss. This suggests
that a secondary intervention has to be performed prior to
thrombosis of the AVF.
To improve outcome, one can perform aggressive sur-
veillance with early secondary interventions. The KDOQI
guidelines recommend surveillance and early intervention.
Lipari et al34 and Tessitore et al35,36 provided evidence that
active surveillance and pre-emptive repair of a subclinical
stenosis reduce the thrombosis rate and prolong the func-
tional life of mature forearm AVFs.36 However, Paulson et
al37 point out that it should also be recognized that unnec-
essary interventions of a stable or slowly growing stenotic
lesion may impair access survival. Whether prospective
monitoring and surveillance can prolong access survival
seems yet unproven. However, it fosters the ability to
Table IV. Patency rates by fistula type
N
Primary patency
1-year (%) 2-year
All patients 347 46.0 36.8
Radiocephalic AVF 179 46.7 37.2
Brachiocephalic AVF 73 47.7 38.0
Basilic vein transposition 62 45.8 36.2
Gracz 33 39.3 32.4
AVF, Arteriovenous fistula.salvage vascular access sites through planning, coordinationf effort, and elective corrective intervention, rather than
rgent procedures or replacement.7,38 Flu et al imple-
ented a new monitoring and surveillance protocol out-
ined in a bimonthly multidisciplinary meeting that resulted
n more effective logistics, and a significant increase in PTA
nd significant decrease in surgical revision, resulting in less
atient morbidity.15 However, too early and aggressive
ntervention may not be cost-effective if the numbers of
rocedures increases disproportionately. We have found a
ompromise position with our surveillance program.
In conclusion, we observed a disappointing primary
atency rate in patients with an autologous AVF, probably
ue to very liberal selection criteria and substantial patient
omorbidity. As a result of frequent, mostly endovascular,
econdary interventions, we obtained strongly improved
atency rates.
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